Srikripa Devarakonda
Stock Analyst at Truist Securities
(0)
# 3906
Out of 5,298 analysts
64
Total ratings
27.27%
Success rate
-9.08%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
INCY Incyte | Maintains: Hold | 74 72 | 60.6 | 18.81% | 9 | Mar 18, 2025 | |
PTGX Protagonist Therapeutics | Maintains: Strong Buy | 60 76 | 44.46 | 70.94% | 2 | Mar 11, 2025 | |
BIIB Biogen | Maintains: Buy | 220 210 | 122.93 | 70.83% | 3 | Feb 13, 2025 | |
LLY Eli Lilly | Maintains: Strong Buy | 1029 1038 | 738.4 | 40.57% | 4 | Feb 3, 2025 | |
ABBV AbbVie | Maintains: Strong Buy | 211 217 | 186.88 | 16.12% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 1126 1004 | 572.76 | 75.29% | 5 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 100 43 | 10 | 330% | 4 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 36 32 | 22.98 | 39.25% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 33 50 | 11.51 | 334.4% | 6 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 36 45 | 26.85 | 67.6% | 4 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 54 53 | 22.03 | 140.58% | 3 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 54 54 | 2.12 | 2447.17% | 1 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 18 15 | 5.17 | 190.14% | 7 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 36 | 9.67 | 272.29% | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 86 70 | 37.42 | 87.07% | 4 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 80 60 | 0.57 | 10426.32% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 38 | n/a | n/a | 3 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 50 34 | n/a | n/a | 2 | Jun 3, 2021 |